Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome

Keyphrases

• Patients with Diabetes Mellitus 100%
• Antiplatelet Therapy 100%
• Acute Coronary Syndrome 100%
• Diabetic Patients 75%
• Diabetic 25%
• Glycoprotein IIb/IIIa Inhibitors 25%
• Ischemic Events 25%
• Non-diabetic 25%
• Clinical Outcomes 25%
• Adverse Events 25%
• Cardiac Events 25%
• Aspirin 25%
• Antiplatelet Drugs 25%
• Clopidogrel 25%
• Platelet Reactivity 25%
• Prasugrel 25%
• Risk Profile 25%
• Clinical High Risk 25%
• Platelet Function 25%
• Ticagrelor 25%
• Patients with Diabetes 25%
• Bleeding Risk 25%
• Without Diabetes 25%
• Atherothrombotic Risk 25%
• Antiplatelet Strategy 25%
• Relative Benefit 25%

Medicine and Dentistry

• Diabetes Mellitus 100%
• Antiplatelet 100%
• Patient with Diabetes 100%
• Acute Coronary Syndrome 100%
• Bleeding 16%
• Glycoprotein IIb/IIIa Inhibitors 16%
• Diabetes 16%
• Adverse Event 16%
• Platelet Reactivity 16%
• Prasugrel 16%
• Clopidogrel 16%
• Acetylsalicylic Acid 16%
• Thrombocyte Function 16%
• Antiplatelet Drug 16%
• Ticagrelor 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Diabetes Mellitus 100%
• Acute Coronary Syndrome 100%
• Antiplatelet 100%
• Fibrinogen Receptor 16%
• Adverse Event 16%
• Bleeding 16%
• Prasugrel 16%
• Clopidogrel 16%
• Acetylsalicylic Acid 16%
• Ticagrelor 16%
• Antithrombocytic Agent 16%